Bank Julius Baer & Co. Ltd Zurich Cuts Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Bank Julius Baer & Co. Ltd Zurich lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 413,870 shares of the medical research company’s stock after selling 17,945 shares during the period. Thermo Fisher Scientific makes up approximately 1.2% of Bank Julius Baer & Co. Ltd Zurich’s portfolio, making the stock its 24th biggest holding. Bank Julius Baer & Co. Ltd Zurich owned approximately 0.11% of Thermo Fisher Scientific worth $219,678,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Meridian Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 2.2% during the 3rd quarter. Meridian Wealth Management LLC now owns 2,147 shares of the medical research company’s stock valued at $1,087,000 after purchasing an additional 47 shares in the last quarter. Strategic Blueprint LLC lifted its position in shares of Thermo Fisher Scientific by 7.8% in the 3rd quarter. Strategic Blueprint LLC now owns 1,124 shares of the medical research company’s stock worth $569,000 after buying an additional 81 shares during the last quarter. Coastline Trust Co lifted its position in Thermo Fisher Scientific by 0.7% in the 3rd quarter. Coastline Trust Co now owns 12,364 shares of the medical research company’s stock valued at $6,258,000 after purchasing an additional 88 shares during the last quarter. Coronation Fund Managers Ltd. lifted its position in Thermo Fisher Scientific by 31.4% in the 3rd quarter. Coronation Fund Managers Ltd. now owns 96,509 shares of the medical research company’s stock valued at $48,850,000 after purchasing an additional 23,086 shares during the last quarter. Finally, DeDora Capital Inc. lifted its position in Thermo Fisher Scientific by 9.8% in the 3rd quarter. DeDora Capital Inc. now owns 1,706 shares of the medical research company’s stock valued at $864,000 after purchasing an additional 152 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on TMO shares. Raymond James lifted their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Evercore ISI boosted their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Robert W. Baird dropped their price target on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a research report on Thursday. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $606.76.

Insider Buying and Selling

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the sale, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Down 0.9 %

Shares of Thermo Fisher Scientific stock traded down $5.29 during trading on Thursday, hitting $572.10. The stock had a trading volume of 1,183,964 shares, compared to its average volume of 1,563,443. The stock has a 50 day simple moving average of $572.61 and a 200 day simple moving average of $529.06. The company has a market capitalization of $218.38 billion, a PE ratio of 36.99, a P/E/G ratio of 2.42 and a beta of 0.80. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping the consensus estimate of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 21.51 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a dividend of $0.39 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.